Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
AMGN Amgen
253.650-1.230-0.48%
Close
01/27 16:00 ET
253.6500.0000.00%
Post Mkt Price 01/27 16:22 ET
High
255.500
Open
254.870
Turnover
535.48M
Low
252.540
Pre Close
254.880
Volume
2.11M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Weybosset Research & Management LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN)
Weybosset Research & Management LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 27.6% during the 3rd quarter, according to the company in its most recent disclosure with the
StockNews.com Lowers Amgen (NASDAQ:AMGN) to Buy
StockNews.com downgraded shares of Amgen (NASDAQ:AMGN – Get Rating) from a strong-buy rating to a buy rating in a research note published on Thursday morning. A number of other analysts also recently
Amgen (AMGN) Scheduled to Post Earnings on Tuesday
Amgen (NASDAQ:AMGN – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, January 31st. Analysts expect Amgen to post earnings of $4.02 per share
StockNews.com Downgrades Amgen (NASDAQ:AMGN) to Buy
Amgen (NASDAQ:AMGN – Get Rating) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Thursday. Several other research analysts have a
Preview -- Barron's
Monday 1/30 Franklin Resources, GE HealthCare Technologies, and NXP Semiconductors report quarterly results. Tuesday 1/31 Advanced Micro Devices, Amgen, Caterpillar, Chubb, Edwards Lifesciences, El
Camarda Financial Advisors LLC Trims Stake in Amgen Inc. (NASDAQ:AMGN)
Camarda Financial Advisors LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 60.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 7,
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Amgen Inc. (AMGN) slipped 0.48% to $253.65 Friday, on what proved to be an all-around favor
Amgen Inc. (NASDAQ:AMGN) Forecasted to Earn FY2023 Earnings of $18.86 Per Share
Amgen Inc. (NASDAQ:AMGN – Get Rating) – Analysts at William Blair lifted their FY2023 earnings per share estimates for shares of Amgen in a research report issued on Monday, January 23rd. William
Amgen Inc. Stock Underperforms Thursday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Amgen Inc. (AMGN) shed 0.65% to $254.88 Thursday, on what proved to be an all-around great
AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Company Overview
More
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
CEO： Mr. Robert A. Bradway
Market： NASDAQ
Listing Date： 06/01/1983
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet